Brain Cancer Clinical Trials in Dallas

Showing 41-60 of 170 trials

Imaging Acetadote Metabolism in Glioblastoma

NCT07387666

This goal of this clinical trial is to evaluate how Acetadote affects metabolism in patients with glioblastoma. Drugs like Acetadote, which affect the level of damage in a cell (oxidative stress), may impact brain tumor metabolism and slow the growth of brain tumors. The investigators are evaluating how Acetadote affects glioblastoma metabolism by using MRI-based methods and by determining the changes in metabolism in brain tumor tissue resected from patients with a new diagnosis of glioblastoma.

GlioblastomaGBM

University of Texas Southwestern Medical Center10 participantsStarted Jul 2026

Dallas, Texas, United States

TERMINATEDPhase 2< 1 mile

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

NCT05267106

This is an open-label, monotherapy study of pemigatinib in participants with recurrent glioblastoma (GBM) or other recurrent gliomas, circumscribed astrocytic gliomas, and glioneuronal and neuronal tumors with an activating FGFR1-3 mutation or fusion/rearrangement. This study consists of 2 cohorts, Cohorts A, and B, and will enroll approximately 82 participants into each cohort. Participants will receive pemigatinib 13.5 mg QD on a 2-week on-therapy and 1-week off-therapy schedule as long as they are receiving benefit and have not met any criteria for study withdrawal.

GlioblastomaAdult-type Diffuse Gliomas

Incyte Corporation83 participantsStarted May 2022

Beverly Hills, California, United States • Duarte, California, United States • Fullerton, California, United States +76 more locations

Imaging Acetadote Metabolism in Glioblastoma

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

Brain Cancer Trials in Other Cities

Tofacitinib in Recurrent GBM Patients

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

A Study of Abemaciclib in Recurrent Glioblastoma

Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

9-ING-41 in Pediatric Patients With Refractory Malignancies.

VB-111 in Surgically Accessible Recurrent/Progressive GBM

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma

Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Study

A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)

Other Conditions in Dallas